false 0001725255 0001725255 2024-12-09 2024-12-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 9, 2024

 

 

AdaptHealth Corp.

(Exact name of registrant as specified in its charter)

 

Delaware  001-38399  82-3677704
(State or other jurisdiction of
incorporation)		  (Commission File Number)  (IRS Employer Identification No.)

 

220 West Germantown Pike, Suite 250

Plymouth Meeting, PA

   19462
(Address of principal executive offices)   (Zip Code)
     
(610) 424-4515

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, par value $0.0001 per share   AHCO   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Amendment to Rietkerk Transition, Separation and Release Agreement

 

On December 9, 2024, AdaptHealth Corp. (the “Company”) entered into an amendment (the “Rietkerk Amendment”) to its transition, separation, and release agreement with Shaw Rietkerk, the Company’s Chief Business Officer, dated August 21, 2024, pursuant to which Mr. Rietkerk agreed to reduce his annual base salary from $500,000 to $125,000 commencing on January 1, 2025. The foregoing description of the Rietkerk Amendment is qualified in its entirety by reference to the full text of the Rietkerk Amendment, which is attached as Exhibit 10.1 hereto and incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)  Exhibits

 

Exhibit No. Description
10.1 Amendment to Transition, Separation and Release Agreement between AdaptHealth Corp. and Shaw Rietkerk, dated December 9, 2024.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

- 2 - 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

Dated: December 13, 2024

 

AdaptHealth Corp.  
   
By: /s/ Jason Clemens  
  Name: Jason Clemens  
  Title: Chief Financial Officer  

 

- 3 - 

 

 

Exhibit 10.1

 

Amendment to Transition, Separation, and Release Agreement

 

This amendment, delivered on December 9, 2024, confirms the following understandings and agreements between AdaptHealth Corp. (the “Company”) and Shaw Rietkerk (hereinafter referred to as “you” or “your”).

 

WHEAREAS, the parties entered a “Transition and Separation Agreement” on August 21, 2024, and have agreed to amend section 2. (a) of that agreement to change the annual base pay that you will be paid from January 1, 2025, until the Separation Date (March 31, 2025) to $125,000 per annum. The Company and you agree that all other terms in the “Transition and Separation Agreement” will remain the same.

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date set forth below.

 

  ADAPTHEALTH CORP.
   
  By: /s/ Suzanne Foster
  Name: Suzanne Foster
  Title: Chief Executive Officer
   
  SHAW RIETKERK
   
  /s/ Shaw Rietkerk
  SHAW RIETKERK
   
  Dated: December 9, 2024

 

 

 

v3.24.3
Cover
Dec. 09, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 09, 2024
Entity File Number 001-38399
Entity Registrant Name AdaptHealth Corp.
Entity Central Index Key 0001725255
Entity Tax Identification Number 82-3677704
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 220 West Germantown Pike
Entity Address, Address Line Two Suite 250
Entity Address, City or Town Plymouth Meeting
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19462
City Area Code 610
Local Phone Number 424-4515
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol AHCO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
AdaptHealth (NASDAQ:AHCO)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more AdaptHealth Charts.
AdaptHealth (NASDAQ:AHCO)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more AdaptHealth Charts.